On Tuesday, Shares of General Electric Company (NYSE:GE), gained 4% to $24.96.
General Electric Company was informed today that the European Commission (EC) has approved the projected Alstom power and grid deal and that the Department of Justice has also filed a projected consent decree that would permit the acquisition to close. These clearances pave the way for GE to complete the transaction as early as possible in the fourth quarter.
The EC’s approval is conditional on GE and Alstom fulfilling commitments given to the European Commission in connection with the clearance. Specifically, subject to regulatory approval, GE will divest to Ansaldo Energia, a supplier of power generation plants and components, a segment of Alstom’s heavy-duty gas turbine business. This will comprise:
- Alstom’s GT26 (an F-class gas turbine) product line for new unit sales
- Alstom’s GT36 technology development program, which upon completion would result in an H-class gas turbine product.
- Services contracts for 34 GT26 units. The remainder of Alstom’s gas turbine installed base (about 720 units) will remain with GE.
- In addition, in order to address concerns raised by the DOJ and EC regarding competition for the service of GE gas turbines, GE will divest Alstom’s Power Systems Manufacturing (PSM) business, which provides after-market parts and services for other OEMs’ equipment. GE will receive a license to the PSM intellectual property used to offer after-market services for non-GE gas turbines.
General Electric Company (GE) operates as an infrastructure and financial services company worldwide. The company’s Power and Water segment offers gas, steam and aeroderivative turbines, nuclear reactors, generators, combined cycle systems, controls, and related services; wind turbines; and water treatment services and equipment.
Shares of Exxon Mobil Corporation (NYSE:XOM), inclined 1.44% to $73.50, during its last trading session, as rising crude prices lifted the oil sector yesterday.
Oil benchmarks diverged on Tuesday, as concerns about slowing China growth weighed on U.S. prices while better-than-predictable European economic data boosted Brent crude, the international benchmark, according to WSJ.
Worse-than-predictable trade data out of China added to fears of the slowdown in the world’s No. 2 oil consumer. Oil prices dropped to more than six-year lows last month following a slide in the Chinese stock market and continued concerns about oversupply. WSJ Reports
According to Chinese customs data, China’s crude-oil imports in August fell 13% over the month, pointing to a diminished appetite for crude.
U.S. oil prices wavered between gains and losses Tuesday before settling down 11 cents, or 0.2%, at $45.94 a barrel on the New York Mercantile Exchange. The U.S. market was closed Monday for the Labor Day holiday. WSJ added.
Exxon Mobil Corporation explores for and produces crude oil and natural gas in the United States, Canada/South America, Europe, Africa, Asia, and Australia/Oceania.
Finally, GlaxoSmithKline plc (NYSE:GSK), ended its last trade with 2.22% gain, and closed at $40.57.
GlaxoSmithKline and Theravance, Inc. declared initial results from the Study to Understand Mortality and MorbidITy in COPD (SUMMIT) for Relvar®/Breo® Ellipta® 100/25mcg (fluticasone furoate ‘FF’/vilanterol ‘VI’ or ‘FF/VI’). The study involved 16,485 patients from 43 countries who had chronic obstructive pulmonary disease (COPD) with moderate airflow limitation (FEV1 50-70% predicted) and either a history or raised risk of cardiovascular disease (CVD).
For the primary endpoint of the study, the risk of dying on FF/VI 100/25mcg was 12.2% lower than on placebo over the study period, which was not statistically noteworthy(p=0.137).
For the first of two secondary endpoints, FF/VI 100/25mcg reduced the rate of lung function decline (as measured by forced expiratory volume in one second, ‘FEV1’) by 8mL per year contrast with placebo (p=0.019). As the primary endpoint was not met, statistical significance cannot be inferred from this result. For the other secondary endpoint, the risk of experiencing an on-treatment cardiovascular (CV) event (CV death, myocardial infarction, stroke, unstable angina and transient ischemic attack [TIA]) at any time was 7.4% lower in patients taking FF/VI 100/25mcg as compared to placebo which was not statistically noteworthy(p=0.475).
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, counting vaccines, over-the-counter medicines, and health-related consumer products worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
